Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 4, 2012, Pages 423-436

  Tahara, Atsuo ^a   Kurosaki, Eiji ^a   Yokono, Masanori ^a   Yamajuku, Daisuke ^a   Kihara, Rumi ^a   Hayashizaki, Yuka ^a   Takasu, Toshiyuki ^a   Imamura, Masakazu ^a   Qun, Li ^b   Tomiyama, Hiroshi ^c   Kobayashi, Yoshinori ^c   Noda, Atsushi ^c   Sasamata, Masao ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Astellas Pharma Global Development   (Netherlands)

^c Kotobuki Pharmaceutical Co Ltd   (Japan)

Author keywords

Diabetes; Hyperglycemia; Ipragliflozin; Sodium glucose cotransporter 2; Urinary glucose excretion

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; GLUCOSIDASE; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; ELECTROLYTE BALANCE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE ABSORPTION; KIDNEY TUBULE ABSORPTION; LOW DRUG DOSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA OSMOLALITY; RAT; REPEATED DRUG DOSE; STREPTOZOCIN DIABETES; URINE VOLUME;

ANIMALS; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL TRACT; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED ICR; PHLORHIZIN; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84861544136     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0713-z     Document Type: Article

References (42)

1. Abdul-Ghani MA, DeFronzo RA (2008) Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 14:782-790
2. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM (1984) Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin with-drawal. Diabetes 33:634-642 (Pubitemid 14087554)
3. Baron AD (1998) Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Diabetes Res Clin Pract 40(Suppl):S51-S55
4. Crofford OB (1995) Diabetes control and complications. Annu Rev Med 46:267-279
5. Donath MY, Gross DJ, Cerasi E, Kaiser N (1999) Hyperglycemia-induced ß-cell apoptosis in pancreatic islets ofPsammomys obe-sus during development ofdiabetes. Diabetes 48:738-744 (Pubitemid 29153072)
6. Dörner KM (1977) Quantitative determination oflactose, maltose, and sucrose in urine. Eur J Pediatr 126:45-52 (Pubitemid 8158609)
7. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J (2005) Phlorizin: a review. Diabetes Metab Res Rev 21:31-38
8. Francis J, Zhang J, Farhi A, Carey H, Geller DS (2004) A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 19:2893-2895 (Pubitemid 39480990)
9. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR Washburn WN, Whaley JM (2008) Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57:1723-1729
10. Harmon JS, Gleason CE, Tanaka Y, Poitout V, Robertson RP (2001) Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet cell triacylglycerol content and decreased insulin gene mRNA level in Zucker Diabetic Fatty rats. Diabetes 50:2481-2486 (Pubitemid 33642765)
11. Idris I, Donnelly R (2009) Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 11:79-88
12. Isaji M (2007) Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 8:285-292 (Pubitemid 46557988)
13. Jabbour SA, Goldstein BJ (2008) Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to im-prove glycaemic control in patients with diabetes. Int J Clin Pract 62:1279-1284 (Pubitemid 351977622)
14. Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Kageyama S (2010) ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus. Diabetes 59(Suppl 1):A21 (abstract 75-OR)
15. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y Fujikura H, Isaji M (2007) Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320:323-330 (Pubitemid 46025747)
16. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M (2009) Dapagliflozin, a novel, selective SGLT2 inhibitor, im-proved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85:513-519
17. Leese HJ, Semenza G (1973) On the identity between the small intestinal enzymes phlorizin hydrolase and glycosylceramidase. J Biol Chem 248:8170-8173
18. List JF, Woo V, Morales E, Tang W, Fiedorek FT (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabe-tes. Diabetes Care 32:650-657
19. Magen D, Sprecher E, Zelikovic I, Skorecki K (2005) A novel mis-sense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 67:34-41 (Pubitemid 40019223)
20. Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, Yamasita S (2006) Site of drug absorption after oral administration: assessment ofmem-brane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 29:240-250 (Pubitemid 44602413)
21. Matsuo T, Odaka H, Ikeda H (1992) Effect of an intestinal disaccha-ridase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 55(Suppl):314S-317S
22. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN (2008) Discovery of dapagliflo-zin: a potent, selective renal sodium-dependent glucose cotrans-porter 2 (SGLT2) inhibitor for the treatment oftype 2 diabetes. J Med Chem 51:1145-1149 (Pubitemid 351480378)
23. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T, Kanai Y Endou H (1999) T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794-1800 (Pubitemid 29415199)
24. +-glucose cotransporters in streptozotocin-induced diabetic rats. Biol Pharm Bull 23:1434-1437 (Pubitemid 32016304)
25. +/nucleoside cotransporter. A member of the SGLT family. J Biol Chem 267:3557-3560
26. Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Investig 116:1802-1812 (Pubitemid 44033300)
27. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA (1987a) Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Investig 80:1037-1044 (Pubitemid 18075639)
28. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA (1987b) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Investig 79:1510-1515 (Pubitemid 17099657)
29. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D (2003) Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873-2882 (Pubitemid 37305650)
30. Sonnenblick M, Friedlander Y, Rosin AJ (1993) Diuretic-induced hyponatremia. Review and analysis of 129 reported patients. Chest 103:601-606 (Pubitemid 23070771)
31. Stahl M, Berger W (1999) Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 16:586-590
32. Tsukada J, Tahara A, Tomura Y, Ki W, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A (2001) Effects ofYM471, a nonpeptide AVP V1A and V2 receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol 133:746-754 (Pubitemid 32642881)
33. +/glucose cotransporter. Nature 350:354-356 (Pubitemid 21912230)
34. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
35. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: po-tential role oftubular reabsorption. J Am Soc Nephrol 10:2569-2576
36. van den Heuvel LP, Assink K, Willemsen M, Monnens L (2002) Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 111:544-547 (Pubitemid 36075086)
37. Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P (2002) Effi-cacy and safety ofvoglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 55:99-103 (Pubitemid 34048697)
38. Washburn WN (2009) Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Patents 19:1485-1499
39. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA (1992) Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 263:F459-F465
40. +-glucose cotransporters. Am J Physiol Renal Physiol 280:F10-F18
41. Wright EM, Turk E (2004) The sodium/glucose cotransporter family SLC5. Pflugers Arch 447:510-518
42. Wright EM, Hirayama BA, Loo DF (2007) Active sugar transport in health and disease. J Intern Med 261:32-43 (Pubitemid 46046470)